| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the MS-MRI Center (Drs. Kalkers, Bergers, Castelijns, Walderveen, Bot, and Barkhof), Department of Clinical Epidemiology and Biostatistics (Dr. Adèr), and Department of Neurology (Drs. Kalkers and Polman), VU Medical Center, Amsterdam, the Netherlands.
Address correspondence and reprint requests to Dr. N.F. Kalkers, Department of Neurology, VU Medical Center, De Boelelaan 1117, P.O. Box 7057, 1007 MB Amsterdam, the Netherlands; e-mail: nf.kalkers{at}azvu.nl
Objective: Axonal damage is an important feature of MS pathology and the likely substrate of development of progressive disability. Brain volume measurement on MRI can be used as an overall marker of tissue damage and axonal loss. The authors studied the relation of brain volume measurements with the MS Functional Composite (MSFC) in an attempt to improve the clinico-radiologic association. Methods: In 137 patients with MS (80 relapsing-remitting [RR], 36 secondary progressive [SP], and 21 primary progressive [PP]) and 12 healthy controls, a brain MRI scan was obtained. Patients also underwent MSFC and Expanded Disability Status Scale (EDSS) assessments. MRI analysis included determination of hypointense T1- and hyperintense T2-weighted lesion load, and two brain volume measurements: 1) the parenchymal fraction (PF): whole brain parenchyma/intracranial volume; and 2) the ventricular fraction (VF): ventricular volume/whole brain parenchyma. Results: The median PF was smaller and the median VF larger in the patient group (0.81 for PF and 0.029 for VF) than in the control group (0.87 for PF, p < 0.001; and 0.013 for VF, p < 0.01). For the patient population, moderate correlations were found between brain volume measurements and MSFC (0.36 for PF and -0.40 for VF). Patients with short disease duration showed a correlation of MSFC with both brain and lesion volume measurements on MRI, whereas patients with long disease duration only showed a correlation with brain volume measurements. Conclusion: Brain volume measurements are correlated with disability as assessed by the MSFC. Although in the early phase of the disease the amount of focal demyelination is important, the residual brain volume seems to be more relevant in determining disability in later phases of the disease.
This article has been cited by other articles:
|
|
 |
|
  J Furby, T Hayton, V Anderson, D Altmann, R Brenner, J Chataway, R. Hughes, K. Smith, D. Miller, and R Kapoor Magnetic resonance imaging measures of brain and spinal cord atrophy correlate with clinical impairment in secondary progressive multiple sclerosis Multiple Sclerosis, September 1, 2008; 14(8): 1068 - 1075. [Abstract] [PDF]
|
|
|
|
|
|
D Bar-Zohar, F Agosta, D Goldstaub, and M Filippi Magnetic resonance imaging metrics and their correlation with clinical outcomes in multiple sclerosis: a review of the literature and future perspectives Multiple Sclerosis, July 1, 2008; 14(6): 719 - 727. [Abstract] [PDF]
|
|
|
|
|
|
V Pueyo, J Martin, J Fernandez, C Almarcegui, J Ara, C Egea, L Pablo, and F Honrubia Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis Multiple Sclerosis, June 1, 2008; 14(5): 609 - 614. [Abstract] [PDF]
|
|
|
|
 |
|
 G. F. Wu, E. D. Schwartz, T. Lei, A. Souza, S. Mishra, D. A. Jacobs, C. E. Markowitz, S. L. Galetta, M. L. Nano-Schiavi, L. M. Desiderio, et al. Relation of vision to global and regional brain MRI in multiple sclerosis Neurology, December 4, 2007; 69(23): 2128 - 2135. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Nessler, S. Boretius, C. Stadelmann, A. Bittner, D. Merkler, H.-P. Hartung, T. Michaelis, W. Bruck, J. Frahm, N. Sommer, et al. Early MRI changes in a mouse model of multiple sclerosis are predictive of severe inflammatory tissue damage Brain, August 1, 2007; 130(8): 2186 - 2198. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. A. Gauthier, M. Mandel, C.R.G. Guttmann, B. I. Glanz, S. J. Khoury, R. A. Betensky, and H. L. Weiner Predicting short-term disability in multiple sclerosis Neurology, June 12, 2007; 68(24): 2059 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Banwell, M. Shroff, J. M. Ness, D. Jeffery, S. Schwid, B. Weinstock-Guttman, and for the International Pediatric MS Study Group MRI features of pediatric multiple sclerosis Neurology, April 17, 2007; 68(16_suppl_2): S46 - S53. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L Lopatinskaya, J Zwemmer, B Uitdehaag, K Lucas, C Polman, and L Nagelkerken Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years Multiple Sclerosis, November 1, 2006; 12(6): 704 - 709. [Abstract] [PDF]
|
|
|
|
|
|
V. de Groot, H. Beckerman, B. M. J. Uitdehaag, H. C. W. de Vet, G. J. Lankhorst, C. H. Polman, and L. M. Bouter The usefulness of evaluative outcome measures in patients with multiple sclerosis Brain, October 1, 2006; 129(10): 2648 - 2659. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Ge Multiple Sclerosis: The Role of MR Imaging AJNR Am. J. Neuroradiol., June 1, 2006; 27(6): 1165 - 1176. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Fazekas, P S Sorensen, M Filippi, S Ropele, X Lin, H W Koelmel, O Fernandez, C Pozzilli, P O'Connor, M M. Enriquez, et al. MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS) Multiple Sclerosis, August 1, 2005; 11(4): 433 - 440. [Abstract] [PDF]
|
|
|
|
|
|
J Versijpt, J C Debruyne, K J Van Laere, F De Vos, J Keppens, K Strijckmans, E Achten, G Slegers, R A Dierckx, J Korf, et al. Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study Multiple Sclerosis, April 1, 2005; 11(2): 127 - 134. [Abstract] [PDF]
|
|
|
|
|
|
R. J Fox, E. Fisher, J. Tkach, J.-C. Lee, J. A Cohen, and R. A Rudick Brain atrophy and magnetization transfer ratio following methylprednisolone in multiple sclerosis: short-term changes and long-term implications Multiple Sclerosis, April 1, 2005; 11(2): 140 - 145. [Abstract] [PDF]
|
|
|
|
|
|
E. Pagani, M. A. Rocca, A. Gallo, M. Rovaris, V. Martinelli, G. Comi, and M. Filippi Regional Brain Atrophy Evolves Differently in Patients with Multiple Sclerosis According to Clinical Phenotype AJNR Am. J. Neuroradiol., February 1, 2005; 26(2): 341 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Petzold, M J Eikelenboom, G Keir, D Grant, R H C Lazeron, C H Polman, B M J Uitdehaag, E J Thompson, and G Giovannoni Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study J. Neurol. Neurosurg. Psychiatry, February 1, 2005; 76(2): 206 - 211. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Boneschi, M. Rovaris, G. Comi, and M. Filippi The use of magnetic resonance imaging in multiple sclerosis: lessons learned from clinical trials Multiple Sclerosis, August 1, 2004; 10(4): 341 - 347. [Abstract] [PDF]
|
|
|
|
|
|
V L Stevenson, G T Ingle, D H Miller, and A J Thompson Magnetic resonance imaging predictors of disability in primary progressive multiple sclerosis: a 5-year study Multiple Sclerosis, August 1, 2004; 10(4): 398 - 401. [Abstract] [PDF]
|
|
|
|
|
|
J N. Zwemmer, T van Veen, L van Winsen, G J van Kamp, F Barkhof, C H Polman, and B M. Uitdehaag No major association of A poE genotype with disease characteristics and MRI findings in multiple sclerosis Multiple Sclerosis, June 1, 2004; 10(3): 272 - 277. [Abstract] [PDF]
|
|
|
|
|
|
Y. Ge, O. Gonen, M. Inglese, J. S. Babb, C. E. Markowitz, and R. I. Grossman Neuronal cell injury precedes brain atrophy in multiple sclerosis Neurology, February 24, 2004; 62(4): 624 - 627. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Malmestrom, S. Haghighi, L. Rosengren, O. Andersen, and J. Lycke Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS Neurology, December 23, 2003; 61(12): 1720 - 1725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. van Veen, L. van Winsen, J. B.A. Crusius, N. F. Kalkers, F. Barkhof, A. S. Pena, C. H. Polman, and B. M.J. Uitdehaag {alpha}B-Crystallin genotype has impact on the multiple sclerosis phenotype Neurology, November 11, 2003; 61(9): 1245 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C.-Y. Chen, H.-W. Chung, and M. Liou Measurement of Volumetric Lesion Load in Multiple Sclerosis: Moving from Normal- to Dirty-Appearing White Matter AJNR Am. J. Neuroradiol., November 1, 2003; 24(10): 1929 - 1930. [Full Text] [PDF]
|
|
|
|
|
|
J. J. G. Geurts, G. Wolswijk, L. Bo, P. van der Valk, C. H. Polman, D. Troost, and E. Aronica Altered expression patterns of group I and II metabotropic glutamate receptors in multiple sclerosis Brain, August 1, 2003; 126(8): 1755 - 1766. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.J. Eikelenboom, A. Petzold, R.H.C. Lazeron, E. Silber, M. Sharief, E.J. Thompson, F. Barkhof, G. Giovannoni, C.H. Polman, and B.M.J. Uitdehaag Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy Neurology, January 28, 2003; 60(2): 219 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J Thompson Developing clinical outcome measures in multiple sclerosis: an evolving process Multiple Sclerosis, October 1, 2002; 8(5): 357 - 358. [PDF]
|
|
|
|
|
|
R A Rudick, G Cutter, and S Reingold The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials Multiple Sclerosis, October 1, 2002; 8(5): 359 - 365. [Abstract] [PDF]
|
|
|
|
|
|
R Leigh, J Ostuni, D Pham, A Goldszal, B K Lewis, T Howard, N Richert, H McFarland, and J A Frank Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences Multiple Sclerosis, October 1, 2002; 8(5): 420 - 429. [Abstract] [PDF]
|
|
|
|
 |
|
 N. F. Kalkers, N. Ameziane, J. C. J. Bot, A. Minneboo, C. H. Polman, and F. Barkhof Longitudinal Brain Volume Measurement in Multiple Sclerosis: Rate of Brain Atrophy Is Independent of the Disease Subtype Arch Neurol, October 1, 2002; 59(10): 1572 - 1576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. H. Miller, F. Barkhof, J. A. Frank, G. J. M. Parker, and A. J. Thompson Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance Brain, August 1, 2002; 125(8): 1676 - 1695. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
